Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence. The phase 3 trial SWOG-8814 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) before tamoxifen (CAF-T) added survival benefit to treatment with tamoxifen alone. Optional tumour banking yielded specimens for determination of recurrence score by RT-PCR. In this retrospective analysis, we assessed the effect of recurrence score on disease-free survival by treatment group (tamoxifen vs CAF-T) using Cox regression, adjusting for number of positive nodes. There were 367 specimens (40% of the 927 patients in the tamoxifen and CAF-T groups) with sufficient RNA for analysis (tamoxifen, n=148; CAF-T, n=219). The recurrence score was prognostic in the tamoxifen-alone group (p=0.006; hazard ratio [HR] 2.64, 95% CI 1.33-5.27, for a 50-point difference in recurrence score). There was no benefit of CAF in patients with a low recurrence score (score <18; log-rank p=0.97; HR 1.02, 0.54-1.93), but an improvement in disease-free survival for those with a high recurrence score (score > or =31; log-rank p=0.033; HR 0.59, 0.35-1.01), after adjustment for number of positive nodes. The recurrence score by treatment interaction was significant in the first 5 years (p=0.029), with no additional prediction beyond 5 years (p=0.58), although the cumulative benefit remained at 10 years. Results were similar for overall survival and breast-cancer-specific survival. The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence score. A low recurrence score identifies women who might not benefit from anthracycline-based chemotherapy, despite positive nodes. National Cancer Institute and Genomic Health.
28 references, click to expand
-
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.Cancer. 1978 May;41(5):1649-57 PMID: 348293
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
-
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.Lancet. 2004 Sep 4-10;364(9437):858-68 PMID: 15351193
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol. 2007 Nov 20;25(33):5287-312 PMID: 17954709
-
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.Breast Cancer Res. 2006;8(3):R25 PMID: 16737553
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005 May 14-20;365(9472):1687-717 PMID: 15894097
-
International Web-based consultation on priorities for translational breast cancer research.Breast Cancer Res. 2007;9(6):R81 PMID: 18034879
-
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol. 2008 Sep 1;26(25):4063-71 PMID: 18678838
-
Gene-expression signatures in breast cancer.N Engl J Med. 2009 Feb 19;360(8):790-800 PMID: 19228622
-
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.J Clin Oncol. 2010 Apr 1;28(10):1671-6 PMID: 20065191
-
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.J Clin Oncol. 2006 Aug 10;24(23):3726-34 PMID: 16720680
-
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.Ann Oncol. 2007 Jul;18(7):1133-44 PMID: 17675394
-
Gene expression profiling of breast cancer: a new tumor marker.J Clin Oncol. 2005 Mar 10;23(8):1631-5 PMID: 15755970
-
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.J Clin Oncol. 2005 Oct 10;23(29):7265-77 PMID: 16145055
-
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.J Oncol Pract. 2007 Jul;3(4):182-6 PMID: 20859407
-
REporting recommendations for tumour MARKer prognostic studies (REMARK).Br J Cancer. 2005 Aug 22;93(4):387-91 PMID: 16106245
-
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.Stat Med. 2002 Aug 15;21(15):2175-97 PMID: 12210632
-
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA. 2006 Apr 12;295(14):1658-67 PMID: 16609087
-
HER2 and response to paclitaxel in node-positive breast cancer.N Engl J Med. 2007 Oct 11;357(15):1496-506 PMID: 17928597
-
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.J Natl Cancer Inst. 2008 Feb 20;100(4):252-60 PMID: 18270335
-
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.Ann Oncol. 2009 Aug;20(8):1319-29 PMID: 19535820
-
A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med. 2002 Dec 19;347(25):1999-2009 PMID: 12490681
-
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.Breast. 2009 Oct;18 Suppl 3:S141-5 PMID: 19914534
-
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65 PMID: 12122096
-
Revision of the American Joint Committee on Cancer staging system for breast cancer.J Clin Oncol. 2002 Sep 1;20(17):3628-36 PMID: 12202663
-
Annual hazard rates of recurrence for breast cancer after primary therapy.J Clin Oncol. 1996 Oct;14(10):2738-46 PMID: 8874335
-
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol. 1998 Feb;11(2):155-68 PMID: 9504686
-
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.Breast Cancer Res Treat. 2009 Jul;116(2):295-302 PMID: 18661261
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
